Grainger Elizabeth M, Kim H Sunny, Monk J Paul, Lemeshow Stanley A, Gong Michael, Bahnson Robert R, Clinton Steven K
Department of Internal Medicine, Division of Hematology and Oncology, Ohio State University, Columbus, OH 43210, USA.
Urol Oncol. 2008 Mar-Apr;26(2):125-32. doi: 10.1016/j.urolonc.2007.01.016. Epub 2007 Oct 18.
It is hypothesized that dietary patterns, individual nutrients, and specific prescription and over-the-counter medications may influence prostate carcinogenesis. Little information is available regarding the use of these products among men who are participating in prevention trials targeting prostate cancer.
A total of 92 men (mean age 69 years) participating in the Prostate Cancer Prevention Trial (PCPT) at an academic center were asked to bring all nutritional supplements and medications to regularly scheduled study visits.
Data were collected on 86 of 92 men. We found that 85% of men in the PCPT regularly consumed at least 1 nutritional supplement. The mean (+/-standard deviation) number of dietary supplements consumed per man was 3.3 +/- 3.5 (range 0-21). A multivitamin and multimineral (73%) supplement was the most common product consumed. Single-nutrient supplements regularly consumed included: vitamin E (48%), vitamin C (31%), calcium (24%), and selenium (7%). Of men, 36% reported consumption of herbal products. Medications frequently consumed during the study period that may influence prostate carcinogenesis included nonsteroidal antiinflammatory drugs (57%), antihypertensives (49%), lipid lowering agents (27%), and aspirin (64%).
Participants in the PCPT at an academic center have a high propensity for dietary supplement use. Many, such as vitamin E and selenium, are hypothesized to influence the risk of prostate cancer. Several of the medications commonly consumed, including aspirin, nonsteroidal antiinflammatory drugs, and statins, are being investigated as chemopreventive agents. Investigators designing prostate cancer chemoprevention trials should consider including detailed documentation of exposure to these products that may influence study outcomes.
据推测,饮食模式、个体营养素以及特定的处方药和非处方药可能会影响前列腺癌的发生。关于参与前列腺癌预防试验的男性使用这些产品的情况,目前所知甚少。
在一个学术中心,共有92名参与前列腺癌预防试验(PCPT)的男性(平均年龄69岁)被要求在定期的研究访视时带上所有营养补充剂和药物。
收集了92名男性中86人的数据。我们发现,PCPT中85%的男性经常服用至少1种营养补充剂。每人服用的膳食补充剂平均数量(±标准差)为3.3±3.5(范围为0 - 21)。多种维生素和多种矿物质补充剂(73%)是最常服用的产品。经常服用的单一营养素补充剂包括:维生素E(48%)、维生素C(31%)、钙(24%)和硒(7%)。36%的男性报告服用过草药产品。在研究期间经常服用的可能影响前列腺癌发生的药物包括非甾体抗炎药(57%)、抗高血压药(49%)、降脂药(27%)和阿司匹林(64%)。
在一个学术中心参与PCPT的参与者使用膳食补充剂的倾向较高。许多补充剂,如维生素E和硒,据推测会影响前列腺癌风险。一些经常服用的药物,包括阿司匹林、非甾体抗炎药和他汀类药物,正作为化学预防剂进行研究。设计前列腺癌化学预防试验的研究人员应考虑详细记录这些可能影响研究结果的产品的使用情况。